Mepolizumab (medical benefit) utilization — coverage criteria
Customize your policy alerts
Sign up for all Community-Care policy alerts
Know when Community-Care releases new policies or updates existing guidance.
Monitor payer policy activity
This policy defines medical necessity criteria, quantity limits, authorization periods, and prescribing requirements for mepolizumab across multiple eosinophil-related indications for Community-Care members.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Initial Approval — Asthma
Covered when ALL of the following are met
Prescriber attestation required regarding adherence and non-concomitant targeted immunomodulator use
Initial Approval — Chronic rhinosinusitis with nasal polyps (CRSwNP)
Covered when ALL of the following are met
Nasal endoscopy or sinus CT confirmation required
Initial Approval — Eosinophilic granulomatosis with polyangiitis (EGPA)
Covered when ALL of the following are met
Specialist involvement and corticosteroid trial required
Initial Approval — Hypereosinophilic Syndrome (HES)
Covered when ALL of the following are met
Specialist involvement and prior therapy required
Initial Approval — Chronic Obstructive Pulmonary Disease (COPD)
Covered when ALL of the following are met
Specialist involvement and adherence to triple therapy required
Continuation of Therapy
Covered when ALL of the following are met (per-indication)
Continuation requires documented benefit
Continuation requires documented benefit
Continuation requires documented benefit
Continuation requires documented benefit
Continuation requires documented benefit
Use of mepolizumab in combination with another targeted immunomodulator for asthma or COPD is not permitted. Prescribers must attest that mepolizumab will not be administered concomitantly with any other targeted immunomodulator product for these indications; continuation criteria also require absence of combination use. Failure to confirm non‑concomitant use may result in denial of coverage.
Coverage requires appropriate specialist involvement and documentation specific to each indication. For asthma and COPD, prescriptions must be written by or in consultation with an allergist, pulmonologist, or immunologist. EGPA and HES require specialist prescribing or consultation (EGPA: rheumatologist, allergist, pulmonologist, or immunologist; HES: a specialist experienced in HES such as rheumatologist, allergist, pulmonologist, gastroenterologist, or hematologist).
Eosinophil thresholds and exacerbation history are required where specified: for eosinophilic asthma a baseline blood eosinophil concentration of ≥ 150 cells/µL; for COPD an eosinophil concentration of ≥ 300 cells/µL; for EGPA and HES blood eosinophils must exceed intense thresholds (EGPA: > 1000 cells/µL or >10% of total leukocytes; HES: > 1000 cells/µL).
Prior therapy trials are also required per indication and must be documented: asthma requires prior use of an inhaled corticosteroid plus an additional controller or maximally tolerated ICS/LABA; CRSwNP requires trial of a nasal corticosteroid spray; EGPA requires a trial of oral corticosteroid therapy equivalent to prednisone 7.5 mg/day for ≥4 weeks; HES requires trial of corticosteroids and/or second‑line steroid‑sparing agents; COPD requires adherent use of maintenance triple therapy (LAMA/LABA/ICS). Where continuation is requested, documentation of a positive clinical response is required.
Billing and Laboratory Thresholds
| J2182 | Injection, mepolizumab, 1 mg |
Prior Authorization, Documentation, and Denial Triggers
Prior Authorization Required
Prior authorization is required for mepolizumab (HCPCS code J2182). Requests must include a clear indication and supporting documentation as outlined below. Submit prior authorization requests per payer procedures before drug administration or billing.
- HCPCS: J2182 (Injection, mepolizumab, 1 mg)
Required Prior Therapy Trials
Prior therapy trials are required for initial approval and must be documented in the prior authorization request. For asthma: trial and continued use of an inhaled corticosteroid (ICS) plus at least one additional controller medication, or maximally tolerated ICS/LABA combination therapy, with persistent exacerbations despite adherence. For chronic rhinosinusitis with nasal polyps: trial of a nasal corticosteroid spray that was ineffective, contraindicated, or not tolerated. For EGPA and HES: trial of systemic corticosteroid therapy (EGPA: prednisone ≈7.5 mg/day for ≥4 weeks) or other steroid-sparing agents for HES unless contraindicated or not tolerated. For COPD: adherence to maintenance triple therapy (LAMA/LABA/ICS) with persistent exacerbations.
- Asthma: documentation of adherence to ICS + 1 additional controller or maximally tolerated ICS/LABA and ≥2 exacerbations in past year despite therapy
- CRSwNP: trial of nasal corticosteroid spray ineffective, contraindicated, or not tolerated
- EGPA: trial of oral corticosteroid therapy (prednisone ≈7.5 mg/day for ≥4 weeks) ineffective, contraindicated, or not tolerated
- HES: trial of corticosteroids and/or steroid-sparing agent ineffective, contraindicated, or not tolerated
- COPD: adherence to maintenance triple therapy (LAMA/LABA/ICS) with ≥2 moderate or ≥1 severe exacerbation in past year
Required Documentation
Prescriber specialty and baseline clinical data must be provided with the authorization request. Required documentation includes age, specialty prescriber or documented consultation, confirmed diagnosis, and baseline blood eosinophil concentration where applicable. Also include prior exacerbation history, trials of prior therapies, and attestation that mepolizumab will not be used concurrently with another targeted immunomodulator for the same condition.
- Age of patient
- Specialist prescriber or documented consultation (allergist, pulmonologist, immunologist, rheumatologist, otolaryngologist, hematologist, or other appropriate specialist as indicated)
- Confirmed diagnosis relevant to the requested indication (e.g., eosinophilic asthma, CRSwNP, EGPA, HES, COPD)
- Baseline blood eosinophil concentration (e.g., ≥150 cells/µL for asthma; ≥300 cells/µL for COPD; thresholds per indication)
- History of exacerbations and prior medication trials (see prior therapy trials)
- Prescriber attestation of adherence to controller medications and that therapy will not be combined with another targeted immunomodulator
Denial Triggers
Authorization may be denied if required criteria or documentation are not met. Common reasons for denial include lack of specialist involvement or documented consultation, failure to meet eosinophil or exacerbation thresholds, inadequate or undocumented trials of prior therapies, use in combination with another targeted immunomodulator, or missing baseline laboratory data.
- No specialist prescriber or no documented consultation when required
- Baseline blood eosinophil concentration below indication-specific threshold or not provided
- Insufficient history of exacerbations or failure to document prior controller therapy trials
- Use in combination with another targeted immunomodulator for asthma/COPD
- Missing documentation of prior steroid trials or intolerance/contraindication when required
Background
Mepolizumab is an anti‑eosinophil targeted immunomodulator indicated across multiple eosinophil‑driven conditions. The policy covers its use for eosinophilic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), and eosinophilic phenotypes of COPD when indication‑specific criteria — including specialist involvement, required eosinophil thresholds, prior therapy trials, and demonstration of clinical benefit for continuation — are met.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.